Objective. To evaluate compliance with hyperlipidaemia screening guidelines for cardiovascular disease prevention in RA compared with the general population.
Introduction
The risk of and mortality from cardiovascular diseases (CVD) are increased in RA [1, 2] . It is therefore important that hyperlipidaemia screening be performed in a timely manner in this population, as primary prevention for CVD. Despite this, few studies have evaluated hyperlipidaemia screening in RA [312] .
The objectives of this study were to measure and compare compliance with general population guidelines for hyperlipidaemia screening in RA and general population controls; examine secular trends in hyperlipidaemia screening; and identify who performs the screening and the predictors of compliance with screening guidelines, in the RA population.
Methods

Study design
We conducted a longitudinal study of a population-based prevalent RA cohort with matched general population controls, assembled in 19962006, and followed until December 2010. Administrative health data was used from the entire province of British Columbia (BC). Ethics approval was obtained from the University of British Columbia (UBC). Informed patient consent is not possible or required when using data from administrative health databases for research purposes.
Study sample
RA study sample RA individuals were identified using previously published criteria [13] . RA individuals eligible for general population hyperlipidaemia screening guidelines [14] were selected, that is, males 540 and females 550 years, excluding individuals with hyperlipidaemia, diabetes mellitus (DM) or coronary artery disease (CAD) (because general population guidelines do not apply) prior to RA onset or to attaining eligible age. Hyperlipidaemia, DM and CAD were defined as one or more physician visit or hospitalization with a diagnostic code, or one or more medication for the respective diagnosis. Individuals with follow-up <5 years were excluded as they could not contribute a complete 5-year eligibility period.
General population sample
A control sample was assembled by randomly selecting individuals from the general population (without any diagnosis of RA or other inflammatory arthritis) who were eligible for hyperlipidaemia screening guidelines (i.e. males 540 and females 550 years, without prior hyperlipidaemia, DM or CAD), matched 1:1 to each RA individual on sex, birth and index year. Controls were excluded if follow-up was <5 years.
Data collection
Data were obtained from administrative health databases of BC, including all physician visits and investigations, from Medical Service Plan (MSP) [15] and Hospital Discharge data [16] since January 1990. PharmaNet data [17] provided information on all medications dispensed from pharmacies for all individuals, regardless of funding source, since January 1996. Data were obtained until December 2010.
Outcome assessment
General population screening guideline for hyperlipidaemia
We evaluated compliance with guidelines published by the Canadian Working Group on Hypercholesterolemia and Other Dyslipidaemias, in 2000 [14] . They recommend performing lipid tests (total cholesterol, high-density lipoprotein (HDL), triglyceride and low-density lipoprotein (LDL)) in all asymptomatic males 540 and females 550 years, at least once every 5 years. Lipid testing serves the purpose of screening for hyperlipidaemia and assessing cardiovascular risk. Guideline was considered met if any of the above-mentioned tests were performed. This guideline was selected as a representation of the minimum standard of care for hyperlipidaemia screening applicable to both RA and the general population. More recent Canadian guidelines mimic these recommendations, although screening is recommended earlier in women (age 40 years), and more frequently if cardiovascular risk from Framingham score [18, 19] exceeds a threshold. In the USA, earlier screening (men 535 and women 545) is recommended with similar frequency, or increased frequency if higher CV risk [20] . As such, the guidelines tested represent the minimum recommendation over the time period studied.
Compliance with general population hyperlipidaemia screening guidelines
Compliance was assessed using eligibility periods [21] . Individuals' follow-up time was divided into 5-year eligible periods, starting from the first time individuals reached eligible age for screening, or from index date, whichever occurred later. Individuals were censored when they became ineligible for screening (i.e. developed hyperlipidaemia, DM or CAD), died or follow-up ended, whichever occurred first. Incomplete eligibility periods were excluded from analysis. Compliance was defined as receiving at least one lipid test during eligible periods and was measured as the proportion of eligible periods when compliance was observed. Proportions were calculated: for each patient, with mean compliance rate per patient calculated for each cohort; and using eligibility periods as the unit of analysis (i.e. pooling all the eligible periods for each cohort).
Physicians responsible for ordering lipid tests
Lipid tests were categorized according to whether they were ordered by a rheumatologist, a family physician (FP) or other physician. The proportion of compliant periods where one or more lipid test was performed by each physician type were calculated, separately.
Variable assessment
Comorbidity score
The Romano modification of the Charlson index, excluding RA as a comorbidity, measured overall burden of comorbidities [22, 23] . It was determined using MSP and hospital discharge data in the year prior to the start of each eligibility period.
Predictors of lipid testing
Potential predictive variables selected a priori included: sex, age, urban vs rural residence (from postal codes), Health Authority: Interior, Coastal, Northern, Fraser and Island (from local health area), socioeconomic status using a validated index [24] (divided into quartiles), Romano comorbidity score (0 vs 51), hospitalization in the prior year (yes/no), rheumatologist visit in the prior 5 years (yes/no), physician visit in the prior year (yes/no) and calendar year, measured at the start of each eligibility period.
Statistical analysis
Multivariable generalized estimating equation (GEE) models were used to estimate odds ratios (OR) and 95% CIs of compliance with screening guidelines in RA relative to general population controls, adjusting for age, sex, comorbidity score and the start year of eligibility period. To evaluate secular trends, screening was compared in 5-year periods starting in 199698 vs periods starting in 200305, thus excluding periods overlapping the year 2003.
Multivariable GEE models were used to identify predictors of compliance with screening guidelines in the RA cohort. Potential predictive variables were evaluated in univariate analyses. Reverse step-wise removal of variables was performed based on significance (P > 0.20) and the lowest quasi-likelihood information criterion (QIC). Age-squared was used to test for nonlinear relationship and avoid residual confounding. SAS V9.3 (SAS Institute, Cary, NC, USA) was used for all analyses. Ethics approval was obtained from UBC. No personal identifying information was provided. All procedures were compliant with BC's Freedom of Information and Privacy Protection Act.
Results
The BC population-based cohort included 36 458 RA individuals. Of these, 23 576 were excluded; 19 226 (52.7%) due to hyperlipidaemia, DM or CAD prior to index date, and 4350 (11.9%) never reached eligible age. Therefore, 12 882 RA individuals were matched to general population controls, and 7295 RA and 7269 controls were excluded because follow-up was <5 years, yielding 5587 RA individuals and 5613 controls, contributing 6993 and 7208 5-year eligible periods, respectively. The RA sample had more comorbidities, as reflected by a higher Romano score (Table 1) .
Compliance with lipid screening guideline RA patients had lipid testing in 56.6% of their eligible periods, compared with 59.5% for controls (P < 0.001) ( Table 1 ; 38.8% of RA patients, and 35.8% of controls, were compliant in none of their eligible periods). Whereas, 52.0% of RA patients and 54.7% of controls were compliant in all their eligible periods.
Using eligible periods as the unit of analysis, lipid tests were performed in 56.3% of eligible periods in RA and 59.2% in control cohorts (P < 0.001). In the adjusted GEE model, there was no difference in screening between the two cohorts [aOR (95% CI): 0.97 (0.90, 1.06)].
Compliance with screening guidelines improved over time, in both RA and controls, with greater improvement in RA than controls (interaction between start year of https://academic.oup.com/rheumatology eligible periods and lipid testing in RA relative to controls P < 0.001). Before 2003, RA individuals were less likely to receive a lipid test (23% lower odds) than controls; whereas there was no significant difference after 2003.
Health professional type ordering lipid tests
For RA individuals, FPs ordered one or more lipid test in 98.4% of the periods when a test was ordered. Rheumatologists did so in 3.3%.
Predictors of compliance with hyperlipidaemia screening guideline
We identified a number of significant predictors of not receiving screening (Table 2) : living in Northern Health Authority, having a higher socioeconomic status, more comorbidities (score 51), a hospitalization in the prior year, seeing a rheumatologist in the prior 5 years, and having no physician visits in the prior year. The odds of receiving screening increased until age 58 years, then decreased.
Discussion
We conducted a population-based study of all RA individuals in the province of BC, to evaluate, and compare with general population controls, compliance with general population screening guidelines for hyperlipidaemia, which represents the minimum standard of care for CVD prevention in RA. Overall, we found that compliance with guidelines was sub-optimal in RA, at 56.3%, and did not differ from the general population (aOR = 0.97), despite a higher risk of CVD. Furthermore, over one-third of RA individuals had no hyperlipidaemia screening in their 5 or 10 years of eligible follow-up. However, we did observe an improvement in screening over time, with a greater improvement in RA than the general population. Nonetheless, compliance remained suboptimal, even in the later period, at 65.8% for RA. Additionally, we identified a number of significant predictors of not receiving hyperlipidaemia screening in RA.
Our findings have important clinical implications. Given the excess risk of, and mortality from, CVD in RA [25, 26] , our findings highlight a clinically relevant gap in the care of RA. Regular lipid testing, to screen for hyperlipidaemia and to assess cardiovascular risk, is essential to guide the need for cardiovascular preventive therapy, such as statin medications. Recently updated EULAR recommendations for CVD risk management in RA [27, 28] recommend CVD risk assessment at least once every 5 years, using a CVD risk prediction model according to national guidelines. Our results point to the need to communicate to FPs the excess CVD risk in RA, as per recent quality indicators for cardiovascular care in RA [29] , since we and others have found that FPs order most lipid tests and take responsibility for most primary prevention of RA comorbidities [30, 31] . However, the optimal sharing of responsibilities between rheumatologists and FPs for cardiovascular prevention still needs to be determined. The EULAR recommendations [28] recognize that assignment of responsibility for cardiovascular risk management should be defined locally due to differences in health care systems and priorities. However, rheumatologists should ensure that cardiovascular risk assessment and management is performed. It is important to note that screening only represents the first step in cardiovascular prevention. Risk management, for example, treatment with statin according to lipid results and cardiovascular risk, is equally important.
Strengths of our study include its population-based nature free of selection bias, the longest follow-up to date, and being the first to evaluate secular trends in screening. Other studies evaluated hyperlipidaemia screening in RA [312] . Limitations of these studies include short follow-up [3, 7, 10, 12] , lack of general population controls [4, 6, 8, 9] , evaluating solely FPs screening [10, 12] and not excluding individuals with prior dyslipidaemia [3, 5, 7, 1012] . Results across studies are inconsistent. Some, like ours, found suboptimal testing, with 4563% receiving screening over 13 years of follow-up [4, 810] ; while others found high rates of screening from 81 to 86% over 25 years [5, 6, 11] . Studies with general population controls reported less frequent [11, 12] , no difference [7, 10] or increased [5] testing in RA. Finally, we and others [4, 5, 7] found that FPs ordered most lipid tests. Our study has limitations inherent to observational studies utilizing administrative data, including uncertainty around diagnosis. RA individuals were identified using published criteria [13, 32] . Nonetheless, inclusion of non-RA cases would bias results towards the null. Data includes all tests performed as outpatients, but not during hospitalizations. This may lead to underestimation of testing.
Conclusion
In our population-based RA cohort, compliance with general population guidelines was poor and was similar to general population controls, despite a higher risk of and mortality from, CVD in RA. Although screening improved over time, it remained suboptimal even after 2003. Our results highlight the need to improve awareness of the excess CVD risk in RA, and to screen for risk factors, such as hyperlipidaemia, for cardiovascular risk assessment and management. CVD prevention efforts in RA should involve FPs, as they order most of the lipid tests and given their central role in primary prevention.
